Rebate
发表于 2025-3-25 05:38:37
http://reply.papertrans.cn/47/4633/463216/463216_21.png
违反
发表于 2025-3-25 08:36:19
http://reply.papertrans.cn/47/4633/463216/463216_22.png
MOCK
发表于 2025-3-25 13:10:04
When patents are not enough: Supplementary incentives for pharmaceutical innovation,force exclusive rights to the patented invention for a fixed period of time. The particular strength of the system is that patents offer a reward correlated with the value that consumers obtain from the product. Firms make decisions to invest in innovation based on their own information about the pr
BULLY
发表于 2025-3-25 16:36:33
http://reply.papertrans.cn/47/4633/463216/463216_24.png
打包
发表于 2025-3-25 23:43:13
The use of pay-for-performance for drugs: Can it improve incentives for innovation?,rely “paying for pills”. Hard-pressed health care payers want to know that they are getting what they are paying for — health and other benefits for patients. Pharmaceutical companies are not prepared to accept prices that they think do not reflect the innovative value that their expensive R&D inves
Oversee
发表于 2025-3-26 01:53:21
http://reply.papertrans.cn/47/4633/463216/463216_26.png
innate
发表于 2025-3-26 07:04:09
http://reply.papertrans.cn/47/4633/463216/463216_27.png
Obedient
发表于 2025-3-26 10:44:46
http://reply.papertrans.cn/47/4633/463216/463216_28.png
领先
发表于 2025-3-26 12:41:01
http://reply.papertrans.cn/47/4633/463216/463216_29.png
MIRE
发表于 2025-3-26 20:30:48
http://reply.papertrans.cn/47/4633/463216/463216_30.png